In the future, we may monitor the mutation level of DDIT4 in tissues through detecting the mutation level of DDIT4 in blood samples of pancreatic cancer patients and then realize effective assessments of chemotherapy resistance and poor prognosis. The gene discussed is DDIT4; the disease is familial pancreatic carcinoma.